- Home
- KPRX vs SST Comparison
KPRX vs SST Comparison
Compare KPRX & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | SST |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.9M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KPRX | SST |
|---|---|---|
| Price | $2.67 | $3.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | $10.00 |
| AVG Volume (30 Days) | 11.8K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $266,129,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.76 | $1.35 |
| 52 Week High | $2.95 | $9.30 |
Technical Indicators
Market Signals| Indicator | KPRX | SST |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 57.90 |
| Support Level | $2.45 | $1.73 |
| Resistance Level | $2.72 | $3.72 |
| Average True Range (ATR) | 0.08 | 0.66 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 84.78 | 44.49 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.